Raltitrexed as an Alternative for Colorectal Cancer Patients with 5-FU Cardiotoxicity
Author Information
Author(s): C-H Kohne, P Thuss-Patience, M Friedrich, PT Daniel, A Kretzschmarl, T Benterl, B Bauer, R Dietz, B Dorken
Primary Institution: Robert-Rossle-Klinik and Franz Volhard Klinik, Medizinische Fakultat Charite der Humboldt-Universitat zu Berlin
Hypothesis
Can raltitrexed be safely administered to patients with 5-FU-associated cardiotoxicity?
Conclusion
Raltitrexed can be safely administered to patients with 5-FU-associated cardiotoxicity without evidence of cardiac side effects.
Supporting Evidence
- Both patients experienced cardiotoxicity from 5-FU but tolerated raltitrexed without cardiac side effects.
- Patient 1 had normal coronary arteries and experienced chest pain only after high-dose 5-FU.
- Patient 2 had a history of coronary artery disease but remained stable after receiving raltitrexed.
Takeaway
This study shows that raltitrexed is a safe option for patients who have heart problems caused by another cancer drug called 5-FU.
Methodology
Two case studies of patients with 5-FU-induced cardiotoxicity treated with raltitrexed.
Limitations
The study is based on only two case reports, limiting generalizability.
Participant Demographics
One female patient aged 58 and one male patient aged 62, both with colorectal cancer and a history of cardiotoxicity.
Want to read the original?
Access the complete publication on the publisher's website